SLC5A2 and myocardial infarction: Moreover, because treatment with an SGLT2 inhibitor will invariably affect circulating blood glucose at the time of myocardial infarction in vivo, we harvested the hearts and undertook the experiments in an ex vivo Langendorff model, with perfused glucose concentration controlled in all experiments.